Michael Feigin


Specializing In:

Cancer cell signaling Cancer genetics Three dimensional cell culture Cell biology

Research Interests:

G-protein coupled receptor signaling Noncoding mutations in cancer Pancreatic cancer Breast cancer Melanoma

About Michael Feigin


Roswell Park Comprehensive Cancer Center
  • Associate Professor of Oncology
  • Department of Pharmacology & Therapeutics
  • Director, Experimental Therapeutics Graduate Program


Education and Training:

  • 2007 - PhD - Molecular and Cellular Pharmacology, State University of New York at Stony Brook, Stony Brook, NY


  • 2017 - Cancer biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY


Research Overview:

Our lab seeks to understand the molecular causes of cancer to develop better therapies and improve patient outcome. Through a combination of computational and experimental methods, we study how genes are regulated in cancer, and how changes in gene regulation and cell signaling networks drive tumor progression.

Feigin Lab


Full Publications list on PubMed

Cornwell AC, Tisdale AA, Venkat V, Maraszek KE, Alahmari AA, George A, Attwood K, George M, Rempinski D, Franco-Barraza J, Parker MD, Cortes-Gomez E, Fountzilas C, Cukierman E, Steele NG, Feigin ME. Lorazepam stimulates IL-6 production and is associated with poor survival outcomes in pancreatic cancer. medRxiv. 2023

Alahmari AA, Chaubey AH, Tisdale AA, Schwarz CD, Cornwell AC, Maraszek KE, Paterson EJ, Kim M, Venkat S, Cortes Gomez E, Wang J, Gurova KV, and Feigin ME. CPSF3 inhibition blocks pancreatic cancer cell proliferation through disruption of core histone processing. bioRxiv. May 2022

Doepner M, Lee I, Natale CA, Brathwaite R, Venkat S, Kim SH, Wei Y, Vakoc CR, Capell BC, Katzenellenbogen JA, Katzenellenbogen BS, Feigin ME and Ridky TW. Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling. Science Advances. 2022

Venkat S, Alahmari AA and Feigin ME. Drivers of gene expression dysregulation in pancreatic cancer. Trends in Cancer. 2021

Cornwell AC and Feigin ME. Unintended effects of GPCR-targeted drugs on the cancer phenotype. Trends in Pharmacological Sciences. 2020

Venkat S, Tisdale AA, Schwarz JR, Alahmari AA, Maurer HC, Olive KP, Eng KH and Feigin ME. Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. Genome Research. 2020

Feigin ME*, Garvin T*, Bailey P, Waddell N, Chang DK, Shuai S, Gallinger S, McPherson JD, Grimmond SM, Khurana E, Stein LD, Biankin AV, Schatz MC, Tuveson DA. Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nature Genetics. 2017